FORMERLY FDA-APPROVED · COMPOUNDED ONLY

Sermorelin

The original GHRH peptide. Was FDA-approved as Geref for GH deficiency until the branded product was discontinued in 2008. Compounded sermorelin remains widely used in anti-aging clinics. The gentler, older cousin of CJC-1295.

The 30-second read

Sermorelin is the active 29-amino-acid fragment of growth-hormone-releasing hormone (GHRH(1-29)), essentially what your brain naturally releases to tell the pituitary to make more growth hormone. It was FDA-approved as Geref in 1990 for diagnosing and treating GH deficiency in children and adults. The branded product (Geref) was discontinued in 2008, for commercial reasons, not safety. Today, sermorelin is widely used as a compounded prescription through anti-aging and longevity clinics, particularly in adults whose IGF-1 has dropped with age. It's the older, shorter-acting GHRH peptide; CJC-1295 (No DAC) was developed as an improved version with longer activity. Compounded sermorelin remains in routine clinical use and is a regular subject of off-label longevity protocols.

Why this peptide is on people's radar

Sermorelin has the unusual position of being a real FDA-approved peptide that's effectively no longer sold as a branded product. The original drug, Geref, was approved in 1990 for diagnosing GH deficiency and later for treating short stature in children with GH deficiency. The product was discontinued in 2008, not because of safety problems but because the commercial market was dominated by direct synthetic GH (somatropin), and EMD Serono saw better returns elsewhere. The molecule didn't go away, it just stopped being sold as a brand-name drug.

What did happen: anti-aging and longevity clinics adopted compounded sermorelin as an off-label option for adults whose IGF-1 levels had dropped with age. The pitch is straightforward and biologically reasonable: sermorelin nudges your own pituitary to release GH in a natural pulsatile pattern, rather than overriding the system with synthetic GH replacement. Pulsatile is more physiologic. The downside is that sermorelin is short-acting (about 10 to 20 minutes plasma half-life), so the GH pulse is brief and doses are typically given nightly to align with the body's natural sleep-time GH release.

For research-peptide audiences, sermorelin sits in an interesting middle ground. It's not the exotic newer compound (CJC-1295, Tesamorelin, retatrutide), it's the original, with three decades of clinical track record behind the molecule itself. It's also not a research-only peptide, compounded sermorelin is prescribed by clinicians in licensed practices. The honest characterization: a real, well-characterized GHRH peptide whose branded version went away for business reasons, now living a second life through compounding pharmacies and longevity clinics.

What people are usually trying to do with it

People exploring sermorelin (typically through a longevity or anti-aging clinic) are usually focused on:

  • Restoring IGF-1 levels that have dropped with age
  • Better sleep, especially the slow-wave phase that GH pulses through
  • Holding lean body composition into adulthood
  • Skin and connective-tissue support from elevated IGF-1
  • An alternative to direct GH replacement that preserves natural pulse patterns
  • An option with longer regulatory history than the research-peptide GHRH analogs

What the science actually shows

Sermorelin has more clinical-trial history than any other GHRH analog except Tesamorelin. Plain-English summary:

Pediatric GH deficiency (FDA-approved historical use)

Multiple trials supported the original Geref approval, sermorelin produced GH and IGF-1 elevation and improved growth velocity in children with GH deficiency.1

Diagnostic use

Sermorelin was used as a stimulation test for GH deficiency, a single dose tests whether the pituitary can respond to GHRH stimulation. This use was reliable and preserved through Geref's clinical history.2

Adult GH supplementation (off-label)

Studies of sermorelin in older adults report increases in IGF-1, improvements in body composition (small reductions in fat mass, modest increases in lean mass), and subjective improvements in sleep and energy. Effect sizes are modest and dose-dependent.3

Pulsatile GH release

Pharmacokinetic studies confirm that sermorelin produces brief GH pulses (peak within 30 to 60 minutes, returning to baseline within 2 hours) rather than sustained elevation. The pulsatile pattern is more physiologic than synthetic GH.4

What hasn't been demonstrated

Long-term outcomes (cardiovascular, mortality) for adults using sermorelin off-label for "anti-aging" purposes. Direct head-to-head efficacy comparisons against CJC-1295 (No DAC) at clinically relevant doses. That sermorelin produces meaningfully better outcomes than the research-peptide alternatives, or that the research-peptide alternatives are meaningfully better than sermorelin.

The honest read

What's solid:

Sermorelin is a real GHRH peptide with three decades of clinical history. It was FDA-approved, has a known safety profile from that approval era, and continues to be prescribed by clinicians through compounding pharmacies. Pulsatile GH/IGF-1 elevation is well-documented. For adults with measurable IGF-1 decline working with a longevity or anti-aging clinician, this is one of the better-grounded options in this category.

What's still being worked out:

The off-label adult-anti-aging use case lacks rigorous long-term outcome data. The modest effect size in adult trials means individual responses vary widely. Whether sermorelin produces meaningfully different real-world outcomes than CJC-1295 (No DAC), they engage the same receptor with different durations, has not been studied head-to-head in the adult longevity context.

What's hyped beyond the evidence:

"Anti-aging cure-all" framings. The objective effects on body composition and IGF-1 are real but modest. Subjective improvements in sleep, energy, and well-being from sermorelin protocols are common in clinical reports but have substantial placebo and lifestyle-confound contributions in unblinded settings. Marketing that positions sermorelin as a return to youthful function overstates what a daily IGF-1 nudge actually accomplishes for most adults.

Things to know if you're looking into it

  • How it's used clinically: a small subcutaneous injection at night before bed. The bedtime timing aligns with the body's natural slow-wave-sleep GH pulse.
  • Compounded only as of 2026: the branded Geref product has been off the market since 2008. Sermorelin is available through licensed compounding pharmacies via prescription.
  • FDA Category 2 status: sermorelin appeared on the FDA Category 2 list along with several other GHRH-axis peptides in September 2023, restricting compounding pharmacy access. The April 2026 FDA advisory panel review of compounded peptides included sermorelin in scope alongside BPC-157, TB-500, and others.
  • How it differs from CJC-1295 (No DAC): same target receptor (GHRH), different durability. Sermorelin has a 10–20 minute plasma half-life. CJC-1295 (No DAC) has a 30-minute half-life. Both produce pulsatile GH release; CJC-1295 produces a slightly larger pulse from the same dose, which is why it's often preferred in modern protocols.
  • Often paired with Ipamorelin or other GHS-R agonists: the same synergy logic that drives the CJC-1295/Ipamorelin combo applies to sermorelin/Ipamorelin or sermorelin/GHRP-2 combinations.
  • Athlete bans: sermorelin is on the World Anti-Doping Agency banned list. Competitive athletes will test positive.
  • Healthcare provider involvement: sermorelin is prescription-only and most legitimately accessed through a clinician relationship. Self-administered "research-peptide" sermorelin operates outside both the historical clinical context and the modern compounding pharmacy framework.
  • Specific dosing protocols, mechanism, and full reference list: all in the "Want to go deeper?" section below.

What people often ask

Is sermorelin FDA-approved?

It was. The branded product Geref was FDA-approved in 1990 and discontinued in 2008. As of 2026, no branded sermorelin product is FDA-approved. Compounded sermorelin remains available by prescription through licensed compounding pharmacies, but appeared on the FDA Category 2 list in September 2023.

How does it differ from CJC-1295?

Same general mechanism (both are GHRH analogs binding the GHRH receptor). Sermorelin is essentially natural GHRH(1-29) with a very short half-life (10–20 minutes). CJC-1295 (No DAC) is an engineered version with four amino-acid substitutions that resist DPP-IV breakdown, extending half-life to about 30 minutes. The longer half-life means a larger GH pulse from the same dose. Both are typically dosed at night, often paired with Ipamorelin.

Why was Geref discontinued?

EMD Serono discontinued the branded product in 2008 for commercial reasons, the market for direct synthetic GH (somatropin) had grown, the GHRH-stimulated approach was niche, and the company's portfolio decisions favored other products. The molecule wasn't pulled for safety; it just stopped being sold as a brand-name drug.

Is it safer than direct HGH?

"Safer" is the wrong frame. They're different. Direct HGH replacement produces sustained, non-physiologic GH elevation. Sermorelin produces a brief pulse closer to the body's natural pattern. The pulsatile approach is widely considered more physiologic, though long-term outcome comparisons in healthy adults haven't been rigorously done.

What about side effects?

Generally mild and uncommon, mild flushing or warmth shortly after injection, occasional injection-site reactions, brief lightheadedness. The historical Geref clinical-trial data and three decades of subsequent clinical use support a generally favorable tolerability profile.

Will it raise my IGF-1?

Studies show sermorelin reliably raises IGF-1 levels in adults whose baseline is below age-appropriate ranges. The size of the effect varies by individual and by dose. Whether the IGF-1 elevation translates into the outcomes people hope for (body composition, sleep, energy) is much more individual.

Who shouldn't use it?

People with active or recent malignancy (theoretical concerns about GH/IGF-1 effects on tumor biology), uncontrolled diabetes, severe sleep apnea, or known hypersensitivity. Pregnancy is a contraindication.

FDA and regulatory status

Status as of May 5, 2026: Originally FDA-approved as Geref (1990) for diagnosis of growth hormone deficiency and treatment of GH deficiency in pediatric patients. Branded product (Geref / Geref Diagnostic) discontinued by EMD Serono in 2008 for commercial reasons. As of 2026, no branded sermorelin product is FDA-approved. Sermorelin appeared on the FDA's Category 2 list in September 2023, restricting compounding-pharmacy access under standard pathways. The April 2026 FDA Pharmacy Compounding Advisory Committee review included sermorelin in the scope of peptides under consideration. Status updates land here when they happen.

Want to go deeper? Mechanism, dosing, the Geref clinical history, side-effect profile, and references.

Background and history

Sermorelin acetate is the synthetic 29-amino-acid sequence corresponding to the active N-terminal fragment of human growth-hormone-releasing hormone (GHRH(1-29)). It was developed in the 1980s, FDA-approved in 1990 as Geref by Serono Laboratories (later EMD Serono / Merck KGaA) for diagnosing GH deficiency, and approved in 1997 as Geref for treatment of GH deficiency in pediatric patients. The branded products were discontinued in 2008 for commercial reasons. The molecule has continued in clinical use through compounding pharmacies, particularly in adult anti-aging and longevity practices. Sermorelin appeared on the FDA Category 2 list in September 2023.

Mechanism of action

GHRH receptor activation

Sermorelin binds the GHRH receptor on pituitary somatotrophs, identically to native GHRH. The Gs-coupled signaling cascade increases intracellular cAMP and triggers GH synthesis and release. The resulting GH pulse, in turn, increases hepatic IGF-1 production over hours to days.

Pulsatile release

Sermorelin's short half-life (10–20 minutes) means that GH release is brief and pulsatile, closer to the body's natural rhythm than the sustained elevation produced by direct GH replacement. Bedtime dosing aligns with the body's largest natural GH pulse during slow-wave sleep.

Why CJC-1295 came after

The four amino-acid substitutions in CJC-1295 (No DAC) confer DPP-IV resistance and modestly extend the GH-releasing window. Sermorelin lacks these modifications and gets degraded faster. CJC-1295 (No DAC) is essentially a more durable version of the same idea.

Sermorelin dosing

This is a prescription medication when compounded. Dosing is established by your prescriber.

Pediatric (historical Geref label): 0.03 mg/kg subcutaneous daily at bedtime for treatment of GH deficiency.

Adult (compounded, off-label): typical clinical-practice dosing is 100 to 500 mcg subcutaneous nightly, on an empty stomach, 30 to 60 minutes before bed. Some protocols use higher doses or pair with Ipamorelin.

Treatment duration: ongoing; long-term use is common in adult longevity protocols. Typical IGF-1 response is monitored at 4–8 weeks and dosing adjusted.

Clinical history

Geref pediatric program: the trials supporting the 1990 and 1997 approvals demonstrated GH and IGF-1 elevation and improved growth velocity in children with GH deficiency. Standard pediatric endocrinology endpoints.

Adult studies: several smaller adult trials in the 1990s and 2000s explored sermorelin in age-related GH decline, with reports of modest IGF-1 elevation and small-to-moderate body-composition changes over months of use.

Modern clinical experience: compounded sermorelin has been used in longevity and anti-aging practices for over 15 years. Documentation is largely from clinical practice rather than randomized trials.

Side effects and safety profile

Reported across the Geref clinical-trial program and compounded use:

  • Mild flushing or warmth shortly after injection (common, transient)
  • Injection-site redness or tenderness (common, mild)
  • Headache (uncommon)
  • Mild fluid retention (uncommon)
  • Transient lightheadedness (uncommon)

Theoretical considerations: GH/IGF-1 elevation interacts theoretically with cancer biology, avoid in active malignancy. Cautious use in diabetes (GH can raise blood glucose), sleep apnea, and carpal-tunnel-prone individuals. The historical Geref clinical-trial safety database and three decades of subsequent clinical use support a generally favorable tolerability profile.

References

  1. Frasier SD, Costin G, Lippe BM, et al. (1990). "A dose-response curve for human growth hormone-releasing hormone (1-29)NH2 in growth hormone-deficient children." J Clin Endocrinol Metab, 70(5), 1191–1195. PubMed
  2. Ghigo E, Aimaretti G, Arvat E, Camanni F. (2001). "Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults." Endocrine, 15(1), 29–38. PubMed
  3. Walker RF. (2006). "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" Clin Interv Aging, 1(4), 307–308. PubMed
  4. Sytze van Dam P, Aleman A, de Vries WR, et al. (2000). "Growth hormone, insulin-like growth factor I and cognitive function in adults." Growth Horm IGF Res, 10(suppl B), S69–S73. PubMed
  5. U.S. Food and Drug Administration. "Geref / Geref Diagnostic Prescribing Information" (historical). FDA.gov
  6. U.S. Food and Drug Administration. (2023). "Pharmacy Compounding Guidance. FDA Category 2 List." FDA.gov
For educational and research purposes only. This is not medical advice. The branded sermorelin product (Geref) was FDA-approved historically and discontinued in 2008. Compounded sermorelin is prescription-only and was added to the FDA Category 2 list in September 2023. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.